
-
OpenAI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Extreme rains hit India's premier Darjeeling tea estates
-
Raducanu retires from opening match in Wuhan heat with dizziness
-
UK's Starmer condemns pro-Palestinian protests on Oct 7 anniversary
-
Tokyo stocks hit new record as markets extend global rally
-
Japan's Takaichi eyes expanding coalition, reports say
-
Canadian PM to visit White House to talk tariffs
-
Indonesia school collapse toll hits 67 as search ends
-
Dodgers hold off Phillies, Brewers on the brink
-
Lawrence sparks Jaguars over Chiefs in NFL thriller
-
EU channels Trump with tariffs to shield steel sector
-
Labuschagne out as Renshaw returns to Australia squad for India ODIs
-
Open AI's Fidji Simo says AI investment frenzy 'new normal,' not bubble
-
Tokyo stocks hit new record as Asian markets extend global rally
-
Computer advances and 'invisibility cloak' vie for physics Nobel
-
Nobel literature buzz tips Swiss postmodernist, Australians for prize
-
Dodgers hold off Phillies to win MLB playoff thriller
-
China exiles in Thailand lose hope, fearing Beijing's long reach
-
Israel marks October 7 anniversary as talks held to end Gaza war
-
Indians lead drop in US university visas
-
Colombia's armed groups 'expanding,' warns watchdog
-
Shhhh! California bans noisy TV commercials
-
Trump 'happy' to work with Democrats on health care, if shutdown ends
-
Trump says may invoke Insurrection Act to deploy more troops in US
-
UNESCO board backs Egyptian for chief after US row
-
Greta Thunberg lands in Greece with expelled Gaza flotilla activists
-
Unreachable Nobel winner hiking 'off the grid'
-
Retirement or marketing gimmick? Cryptic LeBron video sets Internet buzzing
-
CAF 'absolutely confident' AFCON will go ahead in protest-hit Morocco
-
Paris stocks slide amid French political upheaval, Tokyo soars
-
EU should scrap ban on new combustion-engine sales: Merz
-
US government shutdown enters second week, no end in sight
-
World MotoGP champion Marquez to miss two races with fracture
-
Matthieu Blazy reaches for the stars in Chanel debut
-
Macron gives outgoing French PM final chance to salvage government
-
Illinois sues to block National Guard deployment in Chicago
-
Exiled Willis succeeds Dupont as Top 14 player of the season
-
Hamas and Israel open talks in Egypt under Trump's Gaza peace plan
-
Mbappe undergoing treatment for 'small niggle' at France camp: Deschamps
-
Common inhalers carry heavy climate cost, study finds
-
Madagascar president taps general for PM in bid to defuse protests
-
Greta Thunberg lands in Greece among expelled Gaza flotilla activists
-
UEFA 'reluctantly' approves European league games in US, Australia
-
Hundreds protest in Madagascar as president to announce new premier
-
Greta Thunberg lands in Greece among Gaza flotilla activists deported from Israel
-
UNESCO board backs Egyptian ex-minister for top job: official
-
Facing confidence vote, EU chief calls for unity
-
Cash-strapped UNHCR shed 5,000 jobs this year
-
Mbappe to have 'small niggle' examined at France camp: Deschamps
-
Brazil's Lula asks Trump to remove tariffs in 'friendly' phone call

What are regulatory T-cells? Nobel-winning science explained
The Nobel Prize in Medicine was awarded on Monday to three scientists for discovering how a particular kind of cell can stop the body's immune system from attacking itself.
The discovery of these "regulatory T-cells" has raised hopes of finding new ways to fight autoimmune diseases and cancer, though treatments based on the work have yet to become widely available.
After Americans Mary Brunkow and Fred Ramsdell and Japan's Shimon Sakaguchi were announced new Nobel laureates at a ceremony in Stockholm, here is what you need to know about their work.
- What is the immune system? -
The immune system is your body's first line of defence against invaders such as microbes that could give you an infection.
Its most powerful weapons are white blood cells called T-cells. They seek out, identify and destroy these invading germs -- or other unwanted outsiders such as cancerous cells -- throughout the body.
But sometimes these T-cells identify the wrong target and attack healthy cells, which causes a range of autoimmune diseases such as type 1 diabetes and lupus.
Enter regulatory T-cells -- also called Tregs -- which the Nobel committee dubbed the body's "security guards".
"They put the brakes on the immune system to prevent it from attacking something that it shouldn't," Jonathan Fisher, head of the innate immune engineering laboratory at University College London, told AFP.
For a long time, it had been thought this crucial regulation role was performed entirely by the thymus, a small gland in the upper chest.
T-cells have things called "receptors" which make sure they can detect the shape of an invading microbe -- such as the famously spiky Covid-19 virus.
When T-cells grow in the thymus, the gland has a way to eliminate any that have receptors which match healthy cells, to avoid friendly fire in the future.
But what if some of these rogue T-cells slip through?
- What did the Nobel winners do? -
Some scientists had once thought there could be some other cell out there, patrolling for escapees.
But by the 1980s, most researchers had abandoned this idea -- except Sakaguchi.
His team took T-cells from one mouse and injected them into another which had no thymus. The mouse was suddenly protected against autoimmune diseases, showing that something other than the gland must be able to fight off self-attacking T-cells.
A decade later, Brunkow and Ramsdell were investigating why the males of a mutated strain of mice called "scurfy" only lived for a few weeks.
In 2021, they were able to prove that a mutation of the gene FOXP3 caused both scurfy and a rare autoimmune disease in humans called IPEX.
Scientists including Sakaguchi were then able to show that FOXP3 controls the development of regulatory T-cells.
- How does this help us? -
A new field of research has been probing exactly what this discovery means for human health.
French immunologist Divi Cornec told AFP that "a defect in regulatory T-cells" can make autoimmune diseases more severe.
These cells also play a "crucial role in preventing transplanted organs from being rejected," Cornec said.
Cancer can also "hijack" regulatory T-cells to help it escape the immune system, Fisher said.
When this happens, the cells crack down too hard on the immune system -- like an overzealous security guard -- and allow the tumour to grow.
- What about new drugs? -
There are now over 200 clinical trials testing treatments involving regulatory T-cells, according to the Nobel ceremony.
However the breakthroughs which won Monday's Nobel have not yet led to a drug that is currently in wide use.
On Monday, Sakaguchi said he hopes the Nobel spurs the field "in a direction where it can be applied in actual bedside and clinical settings".
Fisher emphasised that a lot of progress had been made over the last five years -- and that these things take a lot of time and money.
"There is a big gap between our scientific understanding of the immune system and our ability to investigate it and manipulate it in a lab -- and our ability to actually deliver a safe-in-humans drug product that will have a consistent and beneficial effect," Fisher said.
Z.AlNajjar--SF-PST